tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Camp4 Therapeutics downgraded to Neutral from Overweight at JPMorgan

JPMorgan analyst Anupam Rama downgraded Camp4 Therapeutics (CAMP) to Neutral from Overweight without a price target The company’s private placement provides a cash runway into 2027, but this is balanced by its the lead program CMP-SYNGAP-01 for Syngap-related disorders being in the very early stage, the analyst tells investors in a research note. JPMorgan now sees a long time horizon to patient level value creation for the shares.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1